This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mosca, L. Search for Related Content PubMed PubMed Citation Articles by Mosca, L.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:394.)
© 2004 American Heart Association, Inc.

Editorials

Summary of the American Heart Association’s Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women

Lori Mosca for the Expert Panel/WritingGroup

From the Preventive Cardiology Program, New York-Presbyterian Hospital/Columbia University Medical Center and Weill Cornell Medical College, New York, NY.

Correspondence to Lori Mosca, MD, PhD, New York-Presbyterian Hospital, 622 West 168th Street, PH10-203B, New York, NY 10032. Email ljm10@columbia.edu

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Cardiovascular disease (CVD) is the largest killer of women in the United States.¹ More than 500 000 women die of CVD annually, more than the number of CVD-related deaths in men or related to the next 7 causes of death in women combined.¹ Despite these statistics, a national survey in 2003 by the American Heart Association (AHA) showed that less than half of all women know that CVD is their leading cause of death.² In an effort to raise awareness and educate health care providers and the public about methods to prevent incident and recurrent CVD events, an expert panel was convened to establish evidence-based guidelines for the prevention of CVD in women. The panel consisted of representatives from 11 AHA Scientific Councils and 11 federal and other professional organizations. There were an additional 22 endorsers. Details of the process and the complete guidelines have been published.³

See page e29

Briefly, candidate recommendations for CVD risk-reducing interventions were discussed, prioritized, and then selected for a systematic literature search. Randomized, clinical trials and large, prospective, cohort studies evaluating cardiovascular risk-reducing interventions with a focus on major clinical endpoints (death, myocardial infarction [MI], stroke, revascularization procedure, congestive heart failure, or a composite CVD endpoint), whether or not there were female participants, were included. Nearly 7000 abstracts were identified in the initial search; 1279 were included for full-text screening and 399 studies were included in the summary evidence tables for each recommendation, with sex-specific information if available. The evidence tables are published online . . . [Full Text of this Article]

This article has been cited by other articles:

				R. Matyal Newly Appreciated Pathophysiology of Ischemic Heart Disease in Women Mandates Changes in Perioperative Management: A Core Review Anesth. Analg., July 1, 2008; 107(1): 37 - 50. [Abstract] [Full Text] [PDF]

				M. Barton, M. R. Meyer, and E. Haas Hormone Replacement Therapy and Atherosclerosis in Postmenopausal Women: Does Aging Limit Therapeutic Benefits? Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1669 - 1672. [Full Text] [PDF]